MTHFR gene polymorphisms and methotrexate toxicity in adult patients with hematological malignancies: a meta-analysis

Ming Zhao1, Liang Liang1, Liwei Ji1

  • 1Department of Pharmacy, Beijing Hospital, No. 1 Dahua Road, Dong Dan, Beijing 100730, P. R. China.

Pharmacogenomics
|June 9, 2016
PubMed
Abstract

Insights

The methylenetetrahydrofolate reductase (MTHFR) C677T gene variant is linked to increased methotrexate toxicity in adult hematological cancers. This finding may help predict adverse events in patients undergoing treatment.

Area of Science:

  • Genetics and Genomics
  • Pharmacogenomics
  • Oncology

Background:

  • Methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms are investigated for their association with methotrexate (MTX) toxicity in adult hematological malignancies.
  • Previous research findings on this association remain inconclusive, necessitating further investigation.

Purpose of the Study:

  • To evaluate the predictive role of common MTHFR gene variants in methotrexate toxicity.
  • To pool quantitative data from relevant studies through a meta-analysis.

Main Methods:

  • A meta-analysis was conducted to identify and pool quantitative data from studies examining MTHFR variants and MTX toxicity.
  • Focus was placed on common MTHFR polymorphisms, specifically C677T and A1298C.

Main Results:

  • The MTHFR C677T polymorphism showed a significant association with an increased risk of all-grade and severe hepatic and gastrointestinal toxicities induced by MTX in Caucasian patients, irrespective of MTX dosage.
  • The MTHFR 677T allele was linked to a higher risk of severe mucositis and all-grade hematological toxicity.
  • The MTHFR A1298C polymorphism did not show a significant association with hepatic or hematological toxicity but may offer a protective effect against mucositis and gastrointestinal toxicity.

Conclusions:

  • The MTHFR C677T polymorphism may serve as a valuable predictor for methotrexate toxicity in adult patients with hematological malignancies.
  • Further research can explore the clinical utility of MTHFR genotyping for personalized MTX treatment strategies.

Related Concept Videos

Translation01:31

Translation

Lesson: Translation
Translation is the process of synthesizing proteins from the genetic information carried by messenger RNA (mRNA). Following transcription, it constitutes the final step in the expression of genes. This process is carried out by ribosomes, complexes of protein and specialized RNA molecules. Ribosomes, transfer RNA (tRNA), and other proteins produce a chain of amino acids—the polypeptide—as the end product of translation.
Translation Produces the Building Blocks of Life
Translation01:31

Translation

Lesson: Translation
Translation is the process of synthesizing proteins from the genetic information carried by messenger RNA (mRNA). Following transcription, it constitutes the final step in the expression of genes. This process is carried out by ribosomes, complexes of protein and specialized RNA molecules. Ribosomes, transfer RNA (tRNA), and other proteins produce a chain of amino acids—the polypeptide—as the end product of translation.
Translation Produces the Building Blocks of Life
Mismatch Repair01:20

Mismatch Repair

Organisms are capable of detecting and fixing nucleotide mismatches that occur during DNA replication. This sophisticated process requires identifying the new strand and replacing the erroneous bases with correct nucleotides. Mismatch repair is coordinated by many proteins in both prokaryotes and eukaryotes.
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
Phase II Reactions: Methylation Reactions01:17

Phase II Reactions: Methylation Reactions

Methylation is a phase II biotransformation process involving the attachment of a methyl group to a substrate. Enzymes known as methyltransferases orchestrate this reaction.
The mechanism of methylation unfolds in two stages. The first stage sees a methyltransferase enzyme facilitating the transfer of a methyl group from S-adenosylmethionine (SAM) to the substrate, forming S-adenosylhomocysteine (SAH). The second stage involves further metabolism of SAH into homocysteine, which can be recycled...
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...